6 research outputs found
Enfektif Endokarditin Embolik Komplikasyonları: 2 Olgu Ve Ulusal Literatürün İrdelenmesi
Embolic complications of infective endocarditis: Report of two Cases and review of National Literature Infektif endokarditin embolik komplikasyonları: İki olgu sunumu ve ulusal literatürün i̇rdelenmesi
Two different actinomycosis cases presented with mass, prediagnosed as malignancy in breast and scrotum Skrotum ve memede malign kitle Ön tanısı alan ıki farklı aktinomikoz olgusu
Two tularemia cases with atypical presentation Atipik bulgularla seyreden i̇ki tularemi olgusu
Reactivation rates in patients using biological agents, with resolved HBV infection or isolated anti-HBc IgG positivity
Background/Aims: Tumor necrosis factor-? (TNF-?) inhibitors and ustekunimab are widely used in autoimmune diseases. It is known that these biological agents cause the reactivation of hepatitis B virus (HBV). There is no standardized strategy to prevent the reactiva- tion in patients with evidence of a previous HBV infection. In our study, anti-HBc IgG-positive patients who received a biological agent were evaluated in terms of HBV reactivation. Materials and Methods: Patients who were followed up for the use of biological agents in our clinic were evaluated retrospectively. Pa- tients with isolated anti-HBc IgG positivity were included in the study. The HBV reactivation data were recorded from the patients’ files retrospectively. Results: Two hundred and seventy-eight patients who received biological treatment were evaluated. Twenty-nine patients with isolated anti-HBc IgG positivity or resolved HBV infection were included in the study. The HBV reactivation was seen in 5 patients (17.2%). Of these patients, 3 were using adalimumab, 1 infliximab, and 1 ustekunimab. It was controlled by antiviral therapy that was started in the early period. Conclusion: Drugs that block TNF-? and ustekunimab cause an increase in viral replication. In literature, the HBV reactivation rate was approximately 1% in HBsAg-negative, anti-HBC IgG-positive cases, whereas it was found to be as high as 17.2% in our study. Patients receiving the immunomodulator therapy should be evaluated for HBV serology before treatment and carefully monitored for HBV reac- tivation during and after treatment